Articles / News / Cuba / European Union to Test Cuban Drug Heberprot-P
Monday, July 9, 2012
European Union to Test Cuban Drug Heberprot-P
Havana, Cuba, Jul 9.- A Cuban drug used in the treatment of diabetic foot ulcers is due to be tested by the European Union, a specialist announced in Havana.
Ernesto Lopez, director of the commercial department at the Genetic Engineering and Biotechnology Center, said the pharmaceutical Heberprot-P will be tested in some 700 patients, in a hundred hospitals across the European Union. The clinical test is based on previous assays carried out at healthcare centers in Spain.
According to experts, this will be the most significant diabetic foot research study in the world, from the clinical and scientific perspectives, with great expectations about its results.
The Cuban pharmaceutical, known as Heberprot-P, has become a leading product for the Genetic Engineering and Biotechnology Center, in terms of sales which are expected to translate into more than 100 million dollars this year.
The Havana-based scientific institution developed the one-of-its-kind medication in joint work with the Institute of Angelology and Vascular Surgery.
Heberprot-P has been patented in over 40 countries with 17 sanitary registrations allowing its use by health ministries of other countries.
In Cuba the treatment of diabetic foot ulcers is being administered in 192 healthcare centers and 43 hospitals with major efforts focusing on primary health attention. (RHC).
Most read news ...